Welcome to our dedicated page for Amyris news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on Amyris stock.
Amyris, Inc. (Nasdaq: AMRS) is a pioneering synthetic biotechnology company that leverages its Lab-to-Market™ technology platform to facilitate the world's shift towards sustainable consumption. Founded with the vision of transforming the Clean Health & Beauty and Flavors & Fragrances markets, Amyris specializes in converting plant sugars into essential hydrocarbon molecules, specialty ingredients, and consumer products using innovative bioscience solutions. The company's proprietary technology platform utilizes advanced machine learning, robotics, and artificial intelligence to bring new innovations to market at commercial scale, resulting in products incorporated into over 20,000 items from leading global brands, impacting more than 300 million consumers.
Recently, Amyris has undergone significant changes to optimize its operations and financial health. In June 2023, the company announced the resignation of its President & CEO, John Melo, with Han Kieftenbeld stepping in as Interim CEO while continuing his role as CFO. This leadership change aligns with Amyris' broader strategy to streamline its business and achieve cost reduction targets, including a global reduction in force and collaboration with PricewaterhouseCoopers (PwC) to implement 'Fit-to-Win' cost actions estimated at $250 million.
Further advancing its strategic transformation, Amyris commenced voluntary Chapter 11 proceedings in August 2023 to restructure its operations and financial framework. This restructuring aims to enhance the company's cost structure, capital position, and liquidity, allowing it to refocus on its core competencies in research and development, commercialization, and the application of sustainable ingredients through biofermentation. As part of this effort, Amyris plans to exit from its consumer brands, marketing them for sale while continuing to operate them through retail and e-commerce platforms during the transition.
Amyris has secured $190 million in debtor-in-possession financing from Foris Ventures to support its daily operations and meet its commitments to employees, customers, and partners throughout the restructuring process. The company is committed to maintaining its innovative edge and remains dedicated to introducing sustainable, effective, and accessible products to market, ensuring a path toward profitable growth and sustained cash generation.
More information about Amyris and its ongoing projects and initiatives can be found on their official website, www.amyris.com.
Amyris, a synthetic biotechnology leader, has successfully closed an offering of $690 million in 1.50% convertible senior notes due 2026. The offering, completed on November 15, 2021, will bear interest payable semiannually, commencing May 15, 2022. The notes are convertible into shares of Amyris' common stock at an initial conversion price of approximately $10.75 per share. Proceeds will be used for various corporate purposes, including repaying existing debt and potential acquisitions. The offering may affect future share dilution.
Amyris, based in Emeryville, California, has priced $600 million in aggregate principal amount of 1.50% convertible senior notes due 2026, up from an initial $400 million offering. The notes will mature on November 15, 2026, with an annual interest rate of 1.50%, payable semiannually. The initial conversion price is set at approximately $10.75 per share, reflecting a 35% premium to the closing price of $7.96 on November 9, 2021. Amyris intends to use around $70.5 million for capped call transactions and $51 million to repay senior debt, with remaining proceeds aimed at general corporate purposes.
Amyris, Inc. (Nasdaq: AMRS) announced its intention to offer $400 million in convertible senior notes due 2026, subject to market conditions. The offering will be conducted via private placement to qualified institutional buyers under Rule 144A. An additional $60 million may also be purchased by initial buyers. Proceeds will be used for capped call transactions, repaying existing debts, and general corporate purposes. The notes are convertible under specific conditions, and their redemption can occur from November 20, 2024. The announcement is not an offer to sell or solicit securities.
Amyris (AMRS) reported strong Q3 2021 results, achieving record underlying revenue of $48 million, a 40% year-over-year increase, and record consumer revenue of $23 million, up 89%. Despite facing global supply chain challenges impacting raw material supplies and freight costs, the company launched four new consumer brands and completed three acquisitions. Amyris expects full-year revenue to reach $330 - $370 million, doubling 2020 figures. Key future projects include a joint venture for a COVID-19 vaccine and the construction of a new ingredients plant in Brazil.
Amyris, Inc. (Nasdaq: AMRS) has formed a 50:50 joint venture with ImmunityBio, Inc. (Nasdaq: IBRX) to commercialize a next-generation COVID-19 vaccine. The binding term sheet has been signed, with a definitive agreement expected soon. ImmunityBio will handle vaccine manufacturing post-human trials in South Africa, while Amyris provides its RNA technology and sustainable squalene. The venture aims to deliver one billion doses in 2022, targeting vaccine access in developing countries and addressing supply chain challenges.
Amyris, a leader in synthetic biotechnology, will announce its Q3 financial results for the period ending September 30, 2021, after market close on November 8, 2021. A conference call featuring CEO John Melo and other executives will follow at 1:30 PM PT (4:30 PM ET) to discuss the results and provide updates. Amyris is recognized for its sustainable ingredients in Clean Health, Beauty, and Wellness, serving over 300 million consumers through various brands like Biossance and Purecane.
Amyris, Inc. (Nasdaq: AMRS) announced a licensing agreement for the Onyx genome engineering platform from Inscripta on October 5, 2021. This collaboration aims to enhance the development of sustainable ingredients through automated gene editing, which is expected to improve efficiency and reduce timelines for product innovation. Amyris has successfully commercialized 13 sustainable ingredients used in over 20,000 products, reaching over 300 million consumers, demonstrating a strong market demand for sustainable solutions.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology, successfully held its fourth investor webinar titled "Lab-to-Market, Delivering Disruptive Health and Beauty Products" on September 28, 2021, attended by over 350 investors. CEO John Melo presented Amyris' mission to transition to sustainable consumption, emphasizing technological advancements and manufacturing excellence that support their Lab-to-Market operating system. The session highlighted key products like Hemisqualane for haircare and a THC-free CBG formulated with Squalane for skin conditions. Presentation materials are available on their investor website.
Amyris, a leader in synthetic biotechnology, will host its fourth virtual investor webinar on September 28, 2021, at 1:00 PM ET. The event, titled "Lab-to-Market, Delivering Disruptive Health and Beauty Products", will cover their biotechnology platform, consumer brands, and recent executive additions. Previous webinars, held on December 15, 2020, February 9, 2021, and April 22, 2021, are available for replay. Investors can join via live webcast or call.
Amyris, a leader in synthetic biotechnology (Nasdaq: AMRS), announced its participation in two investor conferences on September 13, 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will feature on-demand presentations starting at 7:00 AM ET, while the Cowen's 2nd Annual Health, Wellness & Beauty Summit will have live presentations at 2:10 PM ET. A webcast and replays will be available on the company's Investor Relations website. Amyris specializes in sustainable ingredients for health, beauty, and flavor markets.
FAQ
What does Amyris, Inc. specialize in?
What is the Lab-to-Market™ technology platform?
Who is the current CEO of Amyris?
What recent strategic changes has Amyris implemented?
How is Amyris supporting its operations during the restructuring?
What is Amyris' 'Fit-to-Win' initiative?
Will Amyris continue to operate its consumer brands?
What is the impact of Amyris' products on the market?
How can stakeholders get more information about Amyris' restructuring?
Where can I find more information about Amyris?
